Bedaquiline fumarate

TargetMol
Product Code: TAR-T21023
Supplier: TargetMol
CodeSizePrice
TAR-T21023-5mg5mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21023-1mL1 mL * 10 mM (in DMSO)£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21023-10mg10mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21023-25mg25mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21023-50mg50mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21023-100mg100mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21023-200mg200mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21023-500mg500mg£485.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections. It blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called diarylquinolines.
CAS:
845533-86-0
Formula:
C36H35BrN2O6
Molecular Weight:
671.588
Pathway:
Microbiology/Virology
Purity:
0.9977
SMILES:
OC(=O)C=CC(O)=O.COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12
Target:
Antibacterial; Antibiotic

References

1. Hafkin J, Hittel N, Martin A, Gupta R. Compassionate Use of Delamanid in Combination with Bedaquiline for the Treatment of MDR-TB. Eur Respir J. 2018 Oct 25. pii: 1801154. doi: 10.1183/13993003.01154-2018. [Epub ahead of print] PubMed PMID: 30361253. 2. Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, Conradie F. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 Oct 25. pii: 1801528. doi: 10.1183/13993003.01528-2018. [Epub ahead of print] PubMed PMID: 30361246. 3. Lopez B, Siqueira de Oliveira R, Pinhata JMW, Chimara E, Pacheco Ascencio E, Puy?n Guerra ZM, Wainmayer I, Simboli N, Del Granado M, Palomino JC, Ritacco V, Martin A. Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region. J Antimicrob Chemother. 2018 Oct 25. doi: 10.1093/jac/dky414. [Epub ahead of print] PubMed PMID: 30358851.